First experience of simultaneous PET/MRI for the early detection of cardiac involvement in patients with Anderson-Fabry disease

[1]  O. Ratib,et al.  Potential Applications of PET/MR Imaging in Cardiology , 2014, Journal of Nuclear Medicine.

[2]  A. Rolfs,et al.  Continuous Cardiac Troponin I Release in Fabry Disease , 2014, PloS one.

[3]  J. Oliveira,et al.  Fibrosis: a key feature of Fabry disease with potential therapeutic implications , 2013, Orphanet Journal of Rare Diseases.

[4]  V. Dilsizian,et al.  SNMMI/ASNC/SCCT Guideline for Cardiac SPECT/CT and PET/CT 1.0* , 2013, The Journal of Nuclear Medicine.

[5]  Martin Rajchl,et al.  Active Cardiac Sarcoidosis: First Clinical Experience of Simultaneous Positron Emission Tomography–Magnetic Resonance Imaging for the Diagnosis of Cardiac Disease , 2013, Circulation.

[6]  James A. White,et al.  The prognostic role of late gadolinium enhancement magnetic resonance imaging in patients with cardiomyopathy. , 2013, The Canadian journal of cardiology.

[7]  S. Nekolla,et al.  Hybrid PET/MR Imaging of the Heart: Potential, Initial Experiences, and Future Prospects , 2013, The Journal of Nuclear Medicine.

[8]  M. Sabbatini,et al.  Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature. , 2012, Molecular genetics and metabolism.

[9]  Titus Kuehne,et al.  Cardiovascular magnetic resonance of myocardial edema using a short inversion time inversion recovery (STIR) black-blood technique: Diagnostic accuracy of visual and semi-quantitative assessment , 2012, Journal of Cardiovascular Magnetic Resonance.

[10]  D. Bluemke,et al.  Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to united states food and drug administration (FDA) guidelines , 2012, Journal of Cardiovascular Magnetic Resonance.

[11]  C. Vargas,et al.  Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. , 2012, Biochimica et biophysica acta.

[12]  S. Borges-Neto,et al.  Utility of FDG PET/CT in inflammatory cardiovascular disease. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[13]  M. Beer,et al.  Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. , 2011, JACC. Cardiovascular imaging.

[14]  H. Ohira,et al.  18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  Pierre Croisille,et al.  Assessment of myocardial fibrosis with cardiovascular magnetic resonance. , 2011, Journal of the American College of Cardiology.

[16]  T. Imaizumi,et al.  Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. , 2010, JACC. Cardiovascular imaging.

[17]  J. Wykrzykowska,et al.  Imaging of Inflamed and Vulnerable Plaque in Coronary Arteries with 18F-FDG PET/CT in Patients with Suppression of Myocardial Uptake Using a Low-Carbohydrate, High-Fat Preparation , 2009, Journal of Nuclear Medicine.

[18]  S. Packman,et al.  Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  M. Beer,et al.  Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy Evidence for a Better Outcome With Early Treatment , 2009 .

[20]  R. Schiffmann,et al.  Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. , 2008, Molecular genetics and metabolism.

[21]  Katherine C. Wu,et al.  Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. , 2008, Journal of the American College of Cardiology.

[22]  G. Kolodny,et al.  Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. , 2008, AJR. American journal of roentgenology.

[23]  J. Oliveira,et al.  Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. , 2008, Molecular genetics and metabolism.

[24]  G. Sambuceti,et al.  Spatial and Temporal Heterogeneity of Regional Myocardial Uptake in Patients Without Heart Disease Under Fasting Conditions on Repeated Whole-Body 18F-FDG PET/CT , 2007, Journal of Nuclear Medicine.

[25]  J. Zamorano,et al.  Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. , 2007, European heart journal.

[26]  M. Salvatore,et al.  MRI characterization of myocardial tissue in patients with Fabry's disease. , 2007, AJR. American journal of roentgenology.

[27]  D. Pennell,et al.  Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. , 2003, European heart journal.

[28]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[29]  R. Schiffmann,et al.  Clinical features of and recent advances in therapy for Fabry disease. , 2000, JAMA.

[30]  R. Schiffmann,et al.  Profile of endothelial and leukocyte activation in fabry patients , 2000, Annals of neurology.

[31]  B J Messmer,et al.  Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  J. Q. Rosso,et al.  Cardiac magnetic resonance imaging illustrating Anderson–Fabry disease progression , 2012 .

[33]  R. Desnick.  α-Galactosidase A deficiency. Fabry disease , 2001 .